Novanta vs Enpro
NOVT and NPO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NOVT and NPO compare
Enpro is the larger company, worth 1.3 times as much as Novanta ($5.6B against $4.4B).
On earnings, Novanta is cheaper: it trades at 73.9× trailing earnings, against 129× for Enpro.
Enpro grew revenue faster over the last twelve months (13.3% versus 7.6% for Novanta).
Novanta keeps more of each dollar of sales as profit, with a net margin of 6.0% compared with 3.6% at Enpro.
Enpro pays a dividend yielding 0.48%; Novanta does not pay one.
Enpro scores higher on the StockData Score (13 against 12 for Novanta), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NOVT | NPO |
|---|---|---|
| Size and price | ||
| Market cap | $4.4B | $5.6B |
| Share price | $115.33 | $265.51 |
| Change, 1 year | 11.1% | 26.5% |
| Change, 5 years | −28.0% | 150% |
| Beta (5Y) | 1.72 | 1.18 |
| Employees | 3,000 | 4,000 |
| StockData Score | ||
| Total score | 12 | 13 (better) |
| Valuation score | 2 (better) | 1 |
| Growth score | 2 | 2 |
| Performance score | 3 (better) | 0 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 73.9× (better) | 129× |
| P/S | 4.2× (better) | 4.6× |
| P/B | 2.7× (better) | 3.5× |
| EV/EBITDA | 25.2× | 21.7× (better) |
| P/FCF | 38.2× | 33.7× (better) |
| FCF yield | 2.6% | 3.0% (better) |
| Fair value | $111.19 | $150.80 |
| Margin of safety | −3.7% (better) | −76.1% |
| Growth | ||
| Revenue growth (TTM) | 7.6% | 13.3% (better) |
| Revenue growth, 5Y average | 10.7% (better) | 7.4% |
| Net income growth (TTM) | 0.66% (better) | −47.9% |
| EPS growth (TTM) | −8.2% (better) | −48.5% |
| EPS growth, 5Y average | 3.3% (better) | −26.1% |
| Profitability | ||
| Gross margin | 44.5% (better) | 42.8% |
| Operating margin | 9.0% | 14.3% (better) |
| Net margin | 6.0% (better) | 3.6% |
| FCF margin | 11.1% | 13.6% (better) |
| Return on equity | 5.1% (better) | 2.9% |
| Return on invested capital | 6.3% | 6.9% (better) |
| Financial health | ||
| Debt / equity | 0.14 (better) | 0.36 |
| Net debt / EBITDA | −3.18 | 1.77 (better) |
| Interest coverage | – | 5.2× |
| Current ratio | 4.57 (better) | 2.28 |
| Altman Z-score | 6.35 (better) | 4.58 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.48% |
| Payout ratio | – | 60.8% |
| Years of dividend growth | – | 4 |
| Dividend growth, 5Y average | – | 3.6% |
| Buyback yield | 1.2% | – |
| Shareholder yield | 1.2% (better) | 0.48% |
| Ownership | ||
| Held by institutions | 119% | 100% |
| Held by insiders | 0.73% | 0.84% |
| Insider net buying, 12 months | −$11.6M | −$2.9M (better) |
| Short interest, % of float | – | 2.4% |
Go deeper
- NOVT stock overview
- NOVT income statement
- NOVT valuation and score
- NPO stock overview
- NPO income statement
- NPO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.